-
Highlights from the EBMT Annual Meeting CD19 CAR-T Therapy in Transformed Follicular Lymphoma: A Real-World Cohort of 43 Patients
The 52nd EBMT Annual Meeting will be held in Madrid, Spain, from March 22 to 25, 2026. As one of the most prominent international meetings in hematology, EBMT brings together experts from around the world to discuss cutting-edge advances in hematopoietic stem cell transplantation and cellular therapies, driving innovation in clinical practice.
-
Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study
The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the leading international forums in hematology, the meeting brings together experts worldwide to present advances in transplantation, cellular immunotherapy, and complication management, and remains an important platform shaping the future of hematologic treatment.
-
EAU26 Afternoon Dialogue | Prof. Peng Zhang: Final Results of the HOPE-03 Study—ADC Plus Immunotherapy Opens a New Era for Bladder Preservation in MIBC
The 2026 European Association of Urology Annual Congress (EAU26), held in London, brought together leading experts from across the globe to discuss the latest advances in urology. Among the highlights, the final results of the HOPE-03 study, led by Prof. Peng Zhang and his team from West China Hospital, Sichuan University, were presented as an…
-
EAU26 Afternoon Dialogue | From Clinical Pain Points to Precision Diagnosis in Prostate Cancer — Insights from Prof. Kan Gong and Prof. Yi Liu’s Team
The 2026 European Association of Urology Annual Congress (EAU26), one of the most prestigious global meetings in urology, brought together leading advances in urologic oncology. Multiple studies on precision diagnosis of prostate cancer from the team led by Prof. Kan Gong and Prof. Yi Liu at Peking University First Hospital were selected for presentation, showcasing…
-
ASCO GU On-site Report | Prof. Anna Wilkins: AI Pathology Model MMAI Breaks the Bottleneck in Prostate Cancer Risk Stratification, Unlocking a New Era of Personalized Genitourinary Oncology
During the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), a major breakthrough drew global attention: the first international external validation of the digital pathology–based AI predictive model MMAI in localized prostate cancer. Oncology Frontier – UroStream conducted an on-site interview with Prof. Anna Wilkins, Honorary Consultant in Clinical Oncology at The…
-
EAU26 Afternoon Dialogue | Prof. Kan Gong: Large-Scale Chinese VHL Cohort Reveals Distinct Mutation Patterns and Clinical Implications
The 2026 European Association of Urology Annual Congress (EAU26), held in London, once again served as a premier platform showcasing cutting-edge advances in urologic oncology. At this year’s meeting, Prof. Kan Gong and his team from Peking University First Hospital presented a series of impactful studies focusing on von Hippel–Lindau (VHL) syndrome–associated renal cell carcinoma…
-
Voices from China at the EBMT Annual Meeting丨Prof. Yue Lu / Prof. Fang Xu: Efficacy and Safety of Blinatumomab as Part of Induction or Early Consolidation Therapy in Newly Diagnosed B-Cell Acute Leukemia
Blinatumomab, a CD19/CD3 bispecific antibody, has demonstrated clear efficacy in relapsed/refractory and MRD-positive B-cell acute lymphoblastic leukemia (B-ALL). Its integration into frontline therapy for newly diagnosed patients is now being actively explored and may reshape treatment paradigms.
-
Voices from China at the EBMT Annual Meeting丨Prof. Zhijie Wei / Fei Pan: From AML to Rare AMKL—Outcomes and Optimization Strategies for Haploidentical Transplantation
aploidentical hematopoietic stem cell transplantation (haplo-HSCT) has become an important curative approach for acute leukemia. However, post-transplant outcomes remain highly heterogeneous, and key determinants as well as optimal donor strategies are not yet fully defined.
Connecting Medical Expertise through Media